Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...

Researchers say in future it may be possible to grow personalized organoids from patient’s own tissue, to test potential treatments in advance.

IBP-9414 will be the first live biotherapeutic product globally, according to officials at Infant Bacterial Therapeutics in Stockholm.

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Actuate Therapeutics sees opportunity in the daunting numbers associated with metastatic pancreatic cancer: That stage of the disease accounts for approximately 80-85% of all pancreatic cancer ...

“I just can’t make it tonight. You have fun without me.” Across much of the animal kingdom, when infection strikes, social contact shuts down. A study headed by researchers at The Picower Institute ...

This academic-industry partnership reflects the need for a multidisciplinary approach to innovation in cell and gene therapy manufacturing.

EVE is a deep generative model combining evolutionary and human population data to estimate variant deleteriousness on a proteome-wide scale.

The U.S. is AstraZeneca’s largest market by sales and is also home to 19 R&D, manufacturing, and commercial sites.

Precipitation-based purification method could replace current Protein A–reliant methods, significantly reducing manufacturing costs of mAbs.

Sustainable bioprocessing boosts cyanobacterial pigment production for advanced biomedical, imaging, and commercial applications.